• 1
    Scher HI. Prostate carcinoma: defining therapeutic objectives and improving overall outcomes. Cancer Suppl. 2003; 97: 758771.
  • 2
    Denmeade SR, Isaacs JT. Development of prostate cancer treatment: the good news. Prostate. 2004; 58: 211224.
  • 3
    Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev. 2001; 1: 3445.
  • 4
    Eisenberger MA, Simon R, O'Dwyer PJ, et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol. 1985; 3: 827841.
  • 5
    Berliner LJ. Spin labeling theory and applications. New York: Academic Press, 1976.
  • 6
    Hahn SM, Tochner Z, Krishna MC, et al. Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res. 1992; 52: 17501753.
  • 7
    Mitchell JB, DeGraff W, Kaufman D, et al. Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. Arch Biochem Biophys. 1991; 289: 6270.
  • 8
    Gallez B, Bacic G, Goda F, et al. Use of nitroxides for assessing perfusion, oxygenation, and viability of tissues: in vivo EPR and MRI studies. Magn Reson Med. 1996; 35: 97106.
  • 9
    Belkin S, Mehlhorn RJ, Hideg K, Hankovsky O, Packer L. Reduction and destruction rates of nitroxide spin probes. Arch Biochem Biophys. 1987; 256: 232243.
  • 10
    Chen K, Swartz HM. Oxidation of hydroxylamines to nitroxide spin labels in living cells. Biochim Biophys Acta. 1988; 970: 270277.
  • 11
    Krishna MC, Grahame DA, Samuni A, Mitchell JB, Russo A. Oxoammonium cation intermediate in the nitroxide-catalyzed dismutation of superoxide. Proc Natl Acad Sci USA. 1992; 89: 55375541.
  • 12
    Gariboldi MB, Rimoldi V, Supino R, Favini E, Monti E. The nitroxide tempol induces oxidative stress, p21 (WAF1/CIP1), and cell death in HL60 cells. Free Radic Biol Med. 2000; 29: 633641.
  • 13
    Offer T, Russo A, Samuni A. The pro-oxidative activity SOD and nitroxide SOD mimics. FASEB J. 2000; 14: 12151223.
  • 14
    Bragd PL, Besemer AC, van Bekkum H. Bromide-free TEMPO-mediated oxidation of primary alcohol groups in starch and methyl alpha-D-glucopyranoside. Carbohydr Res. 2000; 328: 355363.
  • 15
    Glebska J, Skolimowski J, Kudzin Z, et al. Pro-oxidative activity of nitroxides in their reactions with glutathione. Free Radic Biol Med. 2003; 35: 310316.
  • 16
    Komarov AM, Joseph J, Lai CS. In vivo pharmacokinetics of nitroxides in mice. Biochem Biophys Res Commun. 1994; 201: 10351042.
  • 17
    Swartz HM, Chen K, Hu HP, Hideg K. Contrast agents for magnetic resonance spectroscopy: a method to obtain increased information in in vivo and in vitro spectroscopy. Magn Reson Med. 1991; 22: 372377.
  • 18
    Krishna MC, DeGraff W, Hankovszky OH, et al. Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage. J Med Chem. 1998; 41: 34773492.
  • 19
    Suy S, Mitchell JB, Ehleiter D, Haimovitz-Friedman A, Kasid U. Nitroxides tempol and tempo induce divergent signal transduction pathways in MDA-MB 231 breast cancer cells. J Biol Chem. 1998; 273: 1787117878.
  • 20
    Coopman PJ, Thomas DM, Gehlsen KR, Mueller SC. Integrin α3 b1 participates in the phagocytosis of extracellular matrix molecules by human breast cancer cells. Mol Biol Cell. 1996; 7: 17891804.
  • 21
    Chang SH, Cvetanovic M, Harvey KJ, Komoriya A, Packard BZ, Ucker DS. The effector phase of physiological cell death relies exclusively on the posttranslational activation of resident components. Exp Cell Res. 2002; 277: 1530.
  • 22
    Qi H, Labrie Y, Grenier J, Fournier A, Fillion C, Labrie C. Androgens induce expression of SPAK, a STE20/SPS1-related kinase, in LNCaP human prostate cancer cells. Mol Cell Endocrinol. 2001; 182: 181192.
  • 23
    Ulrix W, Swinnen JV, Heyns W, Verhoeven G. Androgens down-regulate the expression of the human homologue of paternally expressed gene-3 in the prostatic adenocarcinoma cell line LNCaP. Mol Cell Endocrinol. 1999; 155: 6976.
  • 24
    Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem. 1998; 273: 93579360.
  • 25
    Kerr JF. History of the events leading to the formulation of the apoptosis concept. Toxicology. 2002; 181/182: 471474.
  • 26
    Dash BC, El-Deiry WS. Cell cycle checkpoint control mechanisms that can be disrupted in cancer. Methods Mol Biol. 2004; 280: 99161.
  • 27
    Senderowicz AM. Cell cycle modulators for the treatment of lung malignancies. Clin Lung Cancer. 2003; 5: 158168.
  • 28
    Feldkamp MM, Lau N, Guha A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene. 1999; 18: 75147526.
  • 29
    Voest EE, van Faassen E, van Asbeck BS, Neijt JP, Marx JJ. Increased hydrogen peroxide concentration in human tumor cells due to a nitroxide free radical. Biochim Biophys Acta. 1992; 1136: 113118.
  • 30
    Sawada M, Nakashima S, Banno Y, et al. Ordering of ceramide formation, caspase activation, and Bax/Bcl-2 expression during etoposide-induced apoptosis in C6 glioma cells. Cell Death Differ. 2000; 7: 761772.
  • 31
    Gewies A, Rokhlin OW, Cohen MB. Ceramide induces cell death in the human prostatic carcinoma cell lines PC3 and DU145 but does not seem to be involved in Fas-mediated apoptosis. Lab Invest. 2000; 80: 671676.
  • 32
    Li J, Huang C-Y, Zheng R-L, Cui K-R, Li J-F. Hydrogen peroxide induces apoptosis in human hepatoma cells and alters cell redox status. Cell Biol Int. 2000; 24: 923.
  • 33
    Joza N, Susin SA, Daugas E, et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature. 2001; 410: 549554.
  • 34
    Iwai K, Kondo T, Watanabe M, et al. Ceramide increases oxidative damage due to inhibition of catalase by caspase-3-dependent proteolysis in HL-60 cell apoptosis. J Biol Chem. 2003; 278: 98139822.
  • 35
    Gariboldi MB, Ravizza R, Petterino C, Castagnaro M, Finocchiaro G, Monti E. Study of in vitro and in vivo effects of the piperidine nitroxide Tempol—a potential new therapeutic agent for gliomas. Eur J Cancer. 2003; 39: 829837.
  • 36
    Sun S-Y, Yue P, Lotan R. Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol Pharmacol. 1999; 55: 403410.
  • 37
    Liebermann J, Bourg J, Krishna CM, Glass J, Cook JA, Mitchell JB. Pharmacokinetic properties of nitroxide-labeled albumin in mice. Life Sci. 1994; 54: PL503PL509.
  • 38
    Sakabe I, Suy S, Varghese S, Kumar D, Mitchell JB, Kasid U. Tempo treatment of cancer cells modulates the expression of several known and unknown genes [abstract P13-155]. Proceedings of the Annual Meeting of the Radiation Research Society. 2001; 123.
  • 39
    Suy S, Sakabe I, Ahmad I, Mitchell JB, Kasid U. Expression of SHINC-1, a member of the Septin family of proteins, correlates with cell cycle arrest and apoptosis [abstract 203]. Keystone Symposium on Molecular Targets for Cancer Therapy. 2005: 44.